These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 34943991)
1. Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective. Bekhite MM; Schulze PC Cells; 2021 Dec; 10(12):. PubMed ID: 34943991 [TBL] [Abstract][Full Text] [Related]
2. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications. Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518 [TBL] [Abstract][Full Text] [Related]
3. Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening. Ovics P; Regev D; Baskin P; Davidor M; Shemer Y; Neeman S; Ben-Haim Y; Binah O Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023024 [No Abstract] [Full Text] [Related]
4. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Feaster TK; Cadar AG; Wang L; Williams CH; Chun YW; Hempel JE; Bloodworth N; Merryman WD; Lim CC; Wu JC; Knollmann BC; Hong CC Circ Res; 2015 Dec; 117(12):995-1000. PubMed ID: 26429802 [TBL] [Abstract][Full Text] [Related]
5. hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery. Li J; Hua Y; Miyagawa S; Zhang J; Li L; Liu L; Sawa Y Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255277 [TBL] [Abstract][Full Text] [Related]
6. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115 [TBL] [Abstract][Full Text] [Related]
7. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing. Shaheen N; Shiti A; Gepstein L Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902 [TBL] [Abstract][Full Text] [Related]
8. Role of somatic cell sources in the maturation degree of human induced pluripotent stem cell-derived cardiomyocytes. Pianezzi E; Altomare C; Bolis S; Balbi C; Torre T; Rinaldi A; Camici GG; Barile L; Vassalli G Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118538. PubMed ID: 31472168 [TBL] [Abstract][Full Text] [Related]
9. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. Yang X; Papoian T J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688 [TBL] [Abstract][Full Text] [Related]
10. Human Induced Pluripotent Stem Cells Derived from a Cardiac Somatic Source: Insights for an In-Vitro Cardiomyocyte Platform. Lodrini AM; Barile L; Rocchetti M; Altomare C Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31941149 [TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes. Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214 [TBL] [Abstract][Full Text] [Related]
12. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities. Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047 [TBL] [Abstract][Full Text] [Related]